Citation Impact
64 standout
Citing Papers
Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
2024 Standout
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
2024 Standout
Works of Nancy Cross being referenced
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study
2020
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
2018
Author Peers
| Author | Immunology | PFM | Dermatology | Rheumatology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Nancy Cross | 345 | 63 | 198 | 82 | 19 | 395 | |
| Miyachi | 187 | 66 | 115 | 89 | 14 | 403 | |
| Nicole H. DeLarato | 449 | 25 | 3 | 35 | 9 | 973 | |
| Niels-Aage Svendgaard | 46 | 38 | 24 | 30 | 1.8k | ||
| Naohiro Nishiyama | 132 | 65 | 382 | 7 | 46 | 1.2k | |
| Jos Vaessen | 20 | 333 |
All Works
Loading papers...